BRK-B vs CRD-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
CRD-B exhibits significant valuation disconnects, trading at $9.94 despite a Graham Number of $5.58 and an Intrinsic Value of $2.73. While the Piotroski F-Score of 4/9 indicates stable health, this is offset by deteriorating fundamentals, including a -11.20% YoY revenue decline and a -21.1% YoY EPS drop. The technical trend is completely bearish (0/100), and the company has missed 3 of its last 4 earnings estimates. Despite a low forward P/E, the lack of actual growth makes the current premium unjustifiable.
Compare Another Pair
Related Comparisons
BRK-B vs CRD-B: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Crawford & Company (CRD-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.